doi:10.3969/j.issn.1004-583X.2023.07.012

Abstract

CLC Number:

R733.3

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.07.012

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I7/654

Figures/Tables 1

References 28

[1]	Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1):1-9.
[2]	Goel U, Charalampous C, Kapoor P, et al. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma[J]. Blood Cancer J, 2023, 13(1):11. doi: 10.1038/s41408-023-00785-y pmid: 36631454
[3]	Costa LJ, Hungria V, Mohty M, et al. How I treat triple‐class refractory multiple myeloma[J]. Br J Haematol, 2022, 198(2):244-256. doi: 10.1111/bjh.v198.2 URL
[4]	Li D, Li X, Zhou WL, et al. Genetically engineered T cells for cancer immunotherapy[J]. Signal Transduct Target Ther, 2019, 4:35. doi: 10.1038/s41392-019-0070-9
[5]	Yang Q, Li X, Zhang F, et al. Efficacy and safety of CAR-T therapy for relapse or refractory multiple myeloma: A systematic review and meta-analysis[J]. Int J Med Sci, 2021, 18(8):1786-1797. doi: 10.7150/ijms.46811 pmid: 33746596
[6]	Soekojo CY, Chng WJ. Treatment horizon in multiple myeloma[J]. Eur J Haematol, 2022, 109(5):425-440. doi: 10.1111/ejh.v109.5 URL
[7]	Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease[J]. Immunol Rev, 2011, 244(1):115-133. doi: 10.1111/j.1600-065X.2011.01067.x pmid: 22017435
[8]	Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma[J]. N Engl J Med, 2019, 380(18):1726-1737. doi: 10.1056/NEJMoa1817226 URL
[9]	Manier S, Ingegnere T, Escure G, et al. Current state and next-generation CAR-T cells in multiple myeloma[J]. Blood Rev, 2022, 54:100929. doi: 10.1016/j.blre.2022.100929 URL
[10]	Chekol AE, Yibeltal SM, Tadele AF, et al. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma[J]. Front Immunol, 2022, 13:991092. doi: 10.3389/fimmu.2022.991092 URL
[11]	Da VM, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma[J]. Nat Med, 2021, 27(4):616-619. doi: 10.1038/s41591-021-01245-5 pmid: 33619368
[12]	Wang Y, Cao J, Gu W, et al. Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma[J]. J Clin Oncol, 2022, 40(20):2246-2256. doi: 10.1200/JCO.21.01676 URL
[13]	Du J, Jiang H, Dong B, et al. Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)[J]. J Clin Oncol, 2022, 16_suppl(40):8005.
[14]	Friedman KM, Garrett TE, Evans JW, et al. Effective targeting of multiple B-Cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells[J]. Hum Gene Ther, 2018, 29(5):585-601. doi: 10.1089/hum.2018.001 pmid: 29641319
[15]	Munshi NC, Anderson LJ, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma[J]. N Engl J Med, 2021, 384(8):705-716. doi: 10.1056/NEJMoa2024850 URL
[16]	Hansen DK, Sidana S, Peres LC, et al. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: Real-world experience from the myeloma CAR T consortium[J]. J Clin Oncol, 2023, 41(11):2087-2097. doi: 10.1200/JCO.22.01365 URL
[17]	Raje NS, Shah N, Jagannath S, et al. Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma[J]. Blood, 2021, 138:548. doi: 10.1182/blood-2021-146518 URL
[18]	Zhao WH, Wang BY, Chen LJ, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: A phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)[J]. J Hematol Oncol, 2022, 15(1):86. doi: 10.1186/s13045-022-01301-8
[19]	段圆圆, 李子坚. Ciltacabtagene autoleucel——治疗复发难治性多发性骨髓瘤的靶向BCMA CAR-T细胞新型疗法[J]. 中国临床药理学与治疗学, 2022, 27(10):1148-1154.
[20]	Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up[J]. J Clin Oncol, 2023, 41(6):1265-1274. doi: 10.1200/JCO.22.00842 URL
[21]	Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: Phase 1b/2Study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma[J]. Blood, 2021, 138:549. doi: 10.1182/blood-2021-146060 URL
[22]	Gagelmann N, Ayuk F, Atanackovic D, et al. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis[J]. Eur J Haematol, 2020, 104(4):318-327. doi: 10.1111/ejh.13380 pmid: 31883150
[23]	Mei H, Li C, Jiang H, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma[J]. J Hematol Oncol, 2021, 14(1):161. doi: 10.1186/s13045-021-01170-7
[24]	Feng Y, Liu X, Li X, et al. Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma[J]. Oncoimmunology, 2021, 10(1):1959102. doi: 10.1080/2162402X.2021.1959102 URL
[25]	Mailankody S, Liedtke M, Sidana S, et al. Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma[J]. Blood, 2021, 138:651. doi: 10.1182/blood-2021-145572 URL
[26]	Cowan AJ, Pont M, Sather BD, et al. Safety and efficacy of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma[J]. Blood, 2021, 138(Supplement 1):551. doi: 10.1182/blood-2021-154170 URL
[27]	Pont MJ, Hill T, Cole GO, et al. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma[J]. Blood, 2019, 134(19):1585-1597. doi: 10.1182/blood.2019000050 pmid: 31558469
[28]	Chen D, Wang X, Chen Z, et al. Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma[J]. Am J Hematol, 2022, 97(12):E478-E481. doi: 10.1002/ajh.26745 pmid: 36197023

产品名称	例数	试验名称及阶段	靶点	先前LOT	TCR MM (%)	ORR (%)	≥CR (%)	疗效	CRS≥3级 (%)	NT≥3级 (%)
ide-cel^[8]	128	KarMMaI Ⅰ期试验	BCMA	中位:6	84.0	73.0	33.0	mPFS:8.8月 mOS:19.4月	5.0	3.0
bb21217^[9]	72	CRB-402 Ⅰ期试验	BCMA	中位:6	68.0	69.0	28.0	mDOR:17.00月	4.0	4.0
cilta-cel^[10]	74	LEGEND-2 Ⅰ期试验	BCMA	中位:3	-	87.8	73.0	mDOR:23.26月 mPFS:18.04月	9.5	0.0
	97	CARTITUDE-1 1b/2期试验	BCMA	中位:6	87.6	97.9	82.5	mPFS、mOS未达到	4.1	11.3
BM38 CAR-T^[11]	23	Ⅰ期试验	BCMA/CD38	中位:4	-	87.0	52.5	mPFS:17.20月	22.0	0.0
GC012F^[12]	28	Ⅱ期试验	BCMA/CD19	中位:5	96.0	89.3	75.0	mDOR未达到	7.1	0.0
ALLO-715^[13]	42	UNIVERSAL Ⅰ期试验	BCMA	≥3	五重难治:42.9	61.5(DL3、DL4)	NA	mDOR:8.30月	2.0	0.0

产品名称	例数	试验名称及阶段	靶点	先前LOT	TCR MM (%)	ORR (%)	≥CR (%)	疗效	CRS≥3级 (%)	NT≥3级 (%)
ide-cel^[8]	128	KarMMaI Ⅰ期试验	BCMA	中位:6	84.0	73.0	33.0	mPFS:8.8月 mOS:19.4月	5.0	3.0
bb21217^[9]	72	CRB-402 Ⅰ期试验	BCMA	中位:6	68.0	69.0	28.0	mDOR:17.00月	4.0	4.0
cilta-cel^[10]	74	LEGEND-2 Ⅰ期试验	BCMA	中位:3	-	87.8	73.0	mDOR:23.26月 mPFS:18.04月	9.5	0.0
	97	CARTITUDE-1 1b/2期试验	BCMA	中位:6	87.6	97.9	82.5	mPFS、mOS未达到	4.1	11.3
BM38 CAR-T^[11]	23	Ⅰ期试验	BCMA/CD38	中位:4	-	87.0	52.5	mPFS:17.20月	22.0	0.0
GC012F^[12]	28	Ⅱ期试验	BCMA/CD19	中位:5	96.0	89.3	75.0	mDOR未达到	7.1	0.0
ALLO-715^[13]	42	UNIVERSAL Ⅰ期试验	BCMA	≥3	五重难治:42.9	61.5(DL3、DL4)	NA	mDOR:8.30月	2.0	0.0

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 28

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Leng Wantong, Tao Jie. Risk factors of postoperative venous thromboembolism in patients with multiple myeloma [J]. Clinical Focus, 2023, 38(4): 340-345.
[2]	Zhang Lihong, Ma Bing. Correlation between serum β-CTx and TRACP-5b and the severity and prognosis of multiple myeloma bone disease [J]. Clinical Focus, 2021, 36(7): 623-627.
[3]	. [J]. Clinical Focus, 2016, 31(4): 447-450.
[4]	Chen Guanghua;Lin Fengru. Misdiagnosis cause analysis in multiple myeloma [J]. Clinical Focus, 2015, 30(10): 1120-1122.
[5]	. @@ [J]. Clinical Focus, 2015, 30(10): 1186-1188.
[6]	Li Yingwei;Shen Yuanyuan;Li Sasa;Wang Huiping;Zhang Cui;Qin Hui;Zhai Zhimin. Ultra small dose decitabine treatment to elderly patients with myelodysplastic syndrome [J]. Clinical Focus, 2015, 30(7): 773-776.
[7]	. [J]. Clinical Focus, 2015, 30(6): 710-714.
[8]	. [J]. Clinical Focus, 2015, 30(4): 476-480.
[9]	. @@ [J]. Clinical Focus, 2014, 29(12): 1419-0.
[10]	ZHENG Dong. Updates on treatment and standard of multiple myeloma [J]. Clinical Focus, 2014, 29(10): 1130-1133.
[11]	. [J]. Clinical Focus, 2014, 29(7): 803-804.
[12]	HAN Xiu-hua;SUN Li-hua;ZOU Jian;MEN Ya-hong;FAN Xiao-hong;WANG Xue-lian. Protective effect of reduced glutathione on peripheral neuropathy by thalidomide in multiple myeloma [J]. CLINICAL FOCUS, 2014, 29(4): 410-413.
[13]	LIU Zhu-zhen;LI Guang-lun;YANG Jie;CUI Zhong-guang. Effects of different treatments on function of endothelial cells in multiple myeloma patients [J]. CLINICAL FOCUS, 2014, 29(2): 155-158.
[14]	. [J]. Clinical Focus, 2013, 28(1): 102-0.
[15]	CAO Li-xia;XIAO Zhen;GAO Da. Clinical observation of bortezomib plus chemothempy in ten patients with multiple myeloma [J]. Clinical Focus, 2012, 27(24): 2136-2.13721e+007.